par Kirst, H A;Wind, J A;Leeds, J P;Willard-Gallo, Karen
;Debono, M;Bonjouklian, R;Greene, J M;Sullivan, K A;Paschal, J W;Deeter, J B
Référence Journal of medicinal chemistry, 33, 11, page (3086-3094)
Publication Publié, 1990-11
;Debono, M;Bonjouklian, R;Greene, J M;Sullivan, K A;Paschal, J W;Deeter, J BRéférence Journal of medicinal chemistry, 33, 11, page (3086-3094)
Publication Publié, 1990-11
Article révisé par les pairs
| Résumé : | A series of new 9-N-alkyl derivatives of 9(S)-erythromycylamine has been synthesized by reductive alkylation of erythromycylamine with aliphatic aldehydes and sodium cyanoborohydride. Alternative syntheses employing hydrogenation methods have also been developed. These new 9-N-alkyl derivatives possess excellent antimicrobial activity in vitro and in vivo, especially when administered orally to treat experimental infections in mice. From structure-activity studies, 9-N-(1-propyl)erythromycylamine (LY281389) was selected as the most efficacious derivative. These methods have also been extended to the synthesis of some 9-N,N-dialkyl derivatives of erythromycylamine. |



